Added to YB: 2026-09-17
Pitch date: 2026-09-14
INBX [bullish]
Inhibrx Biosciences, Inc.
Author Info
No bio for this author
Company Info
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
Market Cap
$1.6B
Pitch Price
N/A
Price Target
460.00
Dividend
N/A
EV/EBITDA
-13.78
P/E
-12.44
EV/Sales
N/A
Sector
Biotechnology
Category
growth
$INBX Post-Data: Why I Think 106 Worked and Why '27 Could Validate a Much Larger Oncology Franchince
INBX: Inhibrx’s thesis is that INBRX-106 worked: randomized HNSCC data showed 48.3% versus 26.5% ORR and 9.6 versus 4.9 months median PFS, with duration the key result. Underappreciated INBRX-109 provides a second franchise and valuation backbone. Present probability-weighted fair value is $400-$420 per share, centered near $410; key risks are 106’s 35.5% discontinuation rate, HPV+ replication, NSCLC portability and proving 109’s contribution in CRC.
Read full article (9 min)